APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Japanese Encephalitis Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Live Attenuated Japanese Encephalitis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchLive Attenuated Japanese Encephalitis Vaccine Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Japanese Encephalitis Vaccine Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Live Attenuated Japanese Encephalitis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Japanese Encephalitis Vaccine Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Japanese Encephalitis Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Live Attenuated Japanese Encephalitis Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Live Attenuated Japanese Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Japanese Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Japanese Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Live Attenuated Japanese Encephalitis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live Attenuated Japanese Encephalitis Vaccine include Wuhan Institute of Biological Products, Sanofi, Novartis, Lanzhou Institute of Biological Products, Chengdu Institute of Biological Products, Cheng Da Biology, Beijing Temple of Heaven Biological Products, Valneva and Glovax Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live Attenuated Japanese Encephalitis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Attenuated Japanese Encephalitis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Attenuated Japanese Encephalitis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Japanese Encephalitis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Attenuated Japanese Encephalitis Vaccine Segment by Company

Wuhan Institute of Biological Products

Sanofi

Novartis

Lanzhou Institute of Biological Products

Chengdu Institute of Biological Products

Cheng Da Biology

Beijing Temple of Heaven Biological Products

Valneva

Glovax Co., Ltd.

Biocelect Pty Ltd

Bharat Biotech

Live Attenuated Japanese Encephalitis Vaccine Segment by Type

2.5ml

1ml

0.5ml

Live Attenuated Japanese Encephalitis Vaccine Segment by Application

Hospital

Clinic

Live Attenuated Japanese Encephalitis Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Japanese Encephalitis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Japanese Encephalitis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Japanese Encephalitis Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Japanese Encephalitis Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Live Attenuated Japanese Encephalitis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Live Attenuated Japanese Encephalitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Live Attenuated Japanese Encephalitis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Live Attenuated Japanese Encephalitis Vaccine Industry Trends Table 2. Live Attenuated Japanese Encephalitis Vaccine Industry Drivers Table 3. Live Attenuated Japanese Encephalitis Vaccine Industry Opportunities and Challenges Table 4. Live Attenuated Japanese Encephalitis Vaccine Industry Restraints Table 5. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Manufacturers Table 9. Global Live Attenuated Japanese Encephalitis Vaccine Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Live Attenuated Japanese Encephalitis Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Live Attenuated Japanese Encephalitis Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Live Attenuated Japanese Encephalitis Vaccine Manufacturers, Product Type & Application Table 13. Global Live Attenuated Japanese Encephalitis Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Live Attenuated Japanese Encephalitis Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 2.5ml Table 17. Major Manufacturers of 1ml Table 18. Major Manufacturers of 0.5ml Table 19. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Type (2021-2026) & (k units) Table 21. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Type (2027-2032) & (k units) Table 22. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Type (2021-2026) Table 23. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Type (2027-2032) Table 24. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Type (2021-2026) & (k units) Table 26. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Type (2027-2032) & (k units) Table 27. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Type (2021-2026) Table 28. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Clinic Table 31. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Application (2021-2026) & (k units) Table 33. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Application (2027-2032) & (k units) Table 34. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Application (2021-2026) Table 35. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Application (2027-2032) Table 36. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Application (2021-2026) & (k units) Table 38. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Application (2027-2032) & (k units) Table 39. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Application (2021-2026) Table 40. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Application (2027-2032) Table 41. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Live Attenuated Japanese Encephalitis Vaccine Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global Live Attenuated Japanese Encephalitis Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Live Attenuated Japanese Encephalitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2026) & (k units) Table 48. North America Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2027-2032) & (k units) Table 49. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2026) & (k units) Table 51. Europe Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Region (2021-2026) Table 62. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Region (2027-2032) Table 63. Wuhan Institute of Biological Products Company Information Table 64. Wuhan Institute of Biological Products Business Overview Table 65. Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 67. Wuhan Institute of Biological Products Recent Development Table 68. Sanofi Company Information Table 69. Sanofi Business Overview Table 70. Sanofi Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Sanofi Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 72. Sanofi Recent Development Table 73. Novartis Company Information Table 74. Novartis Business Overview Table 75. Novartis Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Novartis Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 77. Novartis Recent Development Table 78. Lanzhou Institute of Biological Products Company Information Table 79. Lanzhou Institute of Biological Products Business Overview Table 80. Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 82. Lanzhou Institute of Biological Products Recent Development Table 83. Chengdu Institute of Biological Products Company Information Table 84. Chengdu Institute of Biological Products Business Overview Table 85. Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 87. Chengdu Institute of Biological Products Recent Development Table 88. Cheng Da Biology Company Information Table 89. Cheng Da Biology Business Overview Table 90. Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 92. Cheng Da Biology Recent Development Table 93. Beijing Temple of Heaven Biological Products Company Information Table 94. Beijing Temple of Heaven Biological Products Business Overview Table 95. Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 97. Beijing Temple of Heaven Biological Products Recent Development Table 98. Valneva Company Information Table 99. Valneva Business Overview Table 100. Valneva Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Valneva Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 102. Valneva Recent Development Table 103. Glovax Co., Ltd. Company Information Table 104. Glovax Co., Ltd. Business Overview Table 105. Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 107. Glovax Co., Ltd. Recent Development Table 108. Biocelect Pty Ltd Company Information Table 109. Biocelect Pty Ltd Business Overview Table 110. Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 112. Biocelect Pty Ltd Recent Development Table 113. Bharat Biotech Company Information Table 114. Bharat Biotech Business Overview Table 115. Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Product Portfolio Table 117. Bharat Biotech Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Live Attenuated Japanese Encephalitis Vaccine Distributors List Table 121. Live Attenuated Japanese Encephalitis Vaccine Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Live Attenuated Japanese Encephalitis Vaccine Product Image Figure 2. Global Live Attenuated Japanese Encephalitis Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Japanese Encephalitis Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Japanese Encephalitis Vaccine Sales (2021-2032) & (k units) Figure 5. Global Live Attenuated Japanese Encephalitis Vaccine Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Live Attenuated Japanese Encephalitis Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 2.5ml Image Figure 9. 1ml Image Figure 10. 0.5ml Image Figure 11. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Type (2021-2032) Figure 14. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Live Attenuated Japanese Encephalitis Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Application (2021-2032) Figure 22. Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Application (2021-2032) Figure 25. North America Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Country (2021-2032) Figure 27. U.S. Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Country (2021-2032) Figure 32. Germany Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 33. France Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Country (2021-2032) Figure 39. China Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 43. India Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Country (2021-2032) Figure 47. Brazil Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile Live Attenuated Japanese Encephalitis Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global Live Attenuated Japanese Encephalitis Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Live Attenuated Japanese Encephalitis Vaccine Revenue (2021-2032) & (US$ Million) Figure 58. North America Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Live Attenuated Japanese Encephalitis Vaccine Revenue (2021-2032) & (US$ Million) Figure 60. Europe Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Live Attenuated Japanese Encephalitis Vaccine Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Live Attenuated Japanese Encephalitis Vaccine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • 2.5ml
  • 1ml
  • 0.5ml
Applications
  • Hospital
  • Clinic
Companies covered
  • Wuhan Institute of Biological Products
  • Sanofi
  • Novartis
  • Lanzhou Institute of Biological Products
  • Chengdu Institute of Biological Products
  • Cheng Da Biology
  • Beijing Temple of Heaven Biological Products
  • Valneva
  • Glovax Co., Ltd.
  • Biocelect Pty Ltd
  • Bharat Biotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Live Attenuated Japanese Encephalitis Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Live Attenuated Japanese Encephalitis Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Live Attenuated Japanese Encephalitis Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Live Attenuated Japanese Encephalitis Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Live Attenuated Japanese Encephalitis Vaccine Market Dynamics
  1. 2.1 Live Attenuated Japanese Encephalitis Vaccine Industry Trends
  2. 2.2 Live Attenuated Japanese Encephalitis Vaccine Industry Drivers
  3. 2.3 Live Attenuated Japanese Encephalitis Vaccine Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Japanese Encephalitis Vaccine Industry Restraints
3 Live Attenuated Japanese Encephalitis Vaccine Market by Manufacturers
  1. 3.1 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Live Attenuated Japanese Encephalitis Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Live Attenuated Japanese Encephalitis Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Live Attenuated Japanese Encephalitis Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Live Attenuated Japanese Encephalitis Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Live Attenuated Japanese Encephalitis Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Live Attenuated Japanese Encephalitis Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Live Attenuated Japanese Encephalitis Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Live Attenuated Japanese Encephalitis Vaccine Tier 1, Tier 2, and Tier 3
4 Live Attenuated Japanese Encephalitis Vaccine Market by Type
  1. 4.1 Live Attenuated Japanese Encephalitis Vaccine Type Introduction
  2. 4.1.1 2.5ml
  3. 4.1.2 1ml
  4. 4.1.3 0.5ml
  5. 4.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Type
  6. 4.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Type (2021-2032)
  8. 4.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Type (2021-2032)
  9. 4.3 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Type
  10. 4.3.1 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Type (2021-2032)
  12. 4.3.3 Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Type (2021-2032)
5 Live Attenuated Japanese Encephalitis Vaccine Market by Application
  1. 5.1 Live Attenuated Japanese Encephalitis Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Application
  5. 5.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Live Attenuated Japanese Encephalitis Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Application
  9. 5.3.1 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Application (2021-2032)
6 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region
  1. 6.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Live Attenuated Japanese Encephalitis Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Live Attenuated Japanese Encephalitis Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Live Attenuated Japanese Encephalitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Live Attenuated Japanese Encephalitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Region
  1. 7.1 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Region
  2. 7.1.1 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Live Attenuated Japanese Encephalitis Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Live Attenuated Japanese Encephalitis Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Live Attenuated Japanese Encephalitis Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Live Attenuated Japanese Encephalitis Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Live Attenuated Japanese Encephalitis Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Wuhan Institute of Biological Products
  2. 8.1.1 Wuhan Institute of Biological Products Company Information
  3. 8.1.2 Wuhan Institute of Biological Products Business Overview
  4. 8.1.3 Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Wuhan Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  6. 8.1.5 Wuhan Institute of Biological Products Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Lanzhou Institute of Biological Products
  20. 8.4.1 Lanzhou Institute of Biological Products Company Information
  21. 8.4.2 Lanzhou Institute of Biological Products Business Overview
  22. 8.4.3 Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lanzhou Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  24. 8.4.5 Lanzhou Institute of Biological Products Recent Developments
  25. 8.5 Chengdu Institute of Biological Products
  26. 8.5.1 Chengdu Institute of Biological Products Company Information
  27. 8.5.2 Chengdu Institute of Biological Products Business Overview
  28. 8.5.3 Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Chengdu Institute of Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  30. 8.5.5 Chengdu Institute of Biological Products Recent Developments
  31. 8.6 Cheng Da Biology
  32. 8.6.1 Cheng Da Biology Company Information
  33. 8.6.2 Cheng Da Biology Business Overview
  34. 8.6.3 Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cheng Da Biology Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  36. 8.6.5 Cheng Da Biology Recent Developments
  37. 8.7 Beijing Temple of Heaven Biological Products
  38. 8.7.1 Beijing Temple of Heaven Biological Products Company Information
  39. 8.7.2 Beijing Temple of Heaven Biological Products Business Overview
  40. 8.7.3 Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Beijing Temple of Heaven Biological Products Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  42. 8.7.5 Beijing Temple of Heaven Biological Products Recent Developments
  43. 8.8 Valneva
  44. 8.8.1 Valneva Company Information
  45. 8.8.2 Valneva Business Overview
  46. 8.8.3 Valneva Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Valneva Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  48. 8.8.5 Valneva Recent Developments
  49. 8.9 Glovax Co., Ltd.
  50. 8.9.1 Glovax Co., Ltd. Company Information
  51. 8.9.2 Glovax Co., Ltd. Business Overview
  52. 8.9.3 Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Glovax Co., Ltd. Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  54. 8.9.5 Glovax Co., Ltd. Recent Developments
  55. 8.10 Biocelect Pty Ltd
  56. 8.10.1 Biocelect Pty Ltd Company Information
  57. 8.10.2 Biocelect Pty Ltd Business Overview
  58. 8.10.3 Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biocelect Pty Ltd Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  60. 8.10.5 Biocelect Pty Ltd Recent Developments
  61. 8.11 Bharat Biotech
  62. 8.11.1 Bharat Biotech Company Information
  63. 8.11.2 Bharat Biotech Business Overview
  64. 8.11.3 Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bharat Biotech Live Attenuated Japanese Encephalitis Vaccine Product Portfolio
  66. 8.11.5 Bharat Biotech Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live Attenuated Japanese Encephalitis Vaccine Value Chain Analysis
  2. 9.1.1 Live Attenuated Japanese Encephalitis Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live Attenuated Japanese Encephalitis Vaccine Production Mode & Process
  6. 9.2 Live Attenuated Japanese Encephalitis Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live Attenuated Japanese Encephalitis Vaccine Distributors
  9. 9.2.3 Live Attenuated Japanese Encephalitis Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst